CorMedix completes $300M acquisition of Melinta Therapeutics - NJBIZ
CorMedix acquires Melinta Therapeutics in a $300M deal, adding Rezzayo and a $120M product portfolio to expand its biopharma growth platform.| NJBIZ
CorMedix acquires Melinta Therapeutics in a $300M deal, adding Rezzayo and a $120M product portfolio to expand its biopharma growth platform.| NJBIZ
